Immunotherapy before surgery shows promise for bladder cancer

NCT ID NCT03520491

First seen Jan 06, 2026 · Last updated May 06, 2026 · Updated 21 times

Summary

This study tests whether giving immunotherapy drugs (nivolumab alone or with ipilimumab) before bladder cancer surgery is safe and does not delay the operation. The goal is to shrink the tumor, making surgery more successful. About 52 people with muscle-invasive bladder cancer who cannot take standard chemotherapy are participating.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities)

    Basking Ridge, New Jersey, 07920, United States

  • Memorial Sloan Kettering Bergen (All Protocol Activities)

    Montvale, New Jersey, 07645, United States

  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Commack (All protocol activities)

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Monmouth (All Protocol Activities)

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Nassau (All protocol activities)

    Uniondale, New York, 11553, United States

  • Memorial Sloan Kettering Westchester (All Protocol Activities)

    Harrison, New York, 10604, United States

Conditions

Explore the condition pages connected to this study.